Get the Stockscreener App
4.66
2.92%
-0.14
Orchestra Biomed Holdings Inc stock is traded at $4.66, with a volume of 373.99K.
It is down -2.92% in the last 24 hours and up +3.33% over the past month.
Orchestra BioMed Holdings Inc is a biomedical innovation company accelerating high-impact technologies to patients through risk-reward sharing partnerships. Its partnership-enabled business model focuses on forging strategic collaborations with medical device companies to drive the commercialization of the products it develops. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension and Virtue Sirolimus AngioInfusionBalloon (SAB) for the treatment of atherosclerotic artery disease.
See More
Previous Close:
$4.80
Open:
$4.8
24h Volume:
373.99K
Relative Volume:
1.24
Market Cap:
$263.13M
Revenue:
$2.76M
Net Income/Loss:
$-49.12M
P/E Ratio:
-3.1067
EPS:
-1.5
Net Cash Flow:
$-46.21M
1W Performance:
+9.91%
1M Performance:
+3.33%
6M Performance:
+59.59%
1Y Performance:
-14.81%
1-Day Range:
$4.475
$4.8887
1-Week Range:
$4.0514
$4.995
52-Week Range:
$2.20
$6.16
Orchestra Biomed Holdings Inc Stock (OBIO) Company Profile
Name
Orchestra Biomed Holdings Inc
Sector
Industry
Phone
646-343-9298
Address
150 UNION SQUARE DRIVE, NEW HOPE
Compare OBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
OBIO
Orchestra Biomed Holdings Inc
|
4.66 | 271.03M | 2.76M | -49.12M | -46.21M | -1.50 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.59 | 117.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
768.00 | 83.72B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
796.00 | 48.79B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
370.91 | 52.62B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
333.99 | 37.39B | 4.98B | 69.59M | 525.67M | 0.5197 |
Orchestra Biomed Holdings Inc Stock (OBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-10-25 | Initiated | TD Cowen | Buy |
| Aug-20-25 | Downgrade | BTIG Research | Buy → Neutral |
| Mar-20-25 | Initiated | BTIG Research | Buy |
| Jan-02-25 | Initiated | Barclays | Overweight |
| Aug-22-24 | Initiated | H.C. Wainwright | Buy |
| Jul-25-24 | Initiated | B. Riley Securities | Buy |
| Jan-19-24 | Initiated | Jefferies | Buy |
| Feb-24-23 | Initiated | Piper Sandler | Overweight |
| Feb-07-23 | Initiated | Chardan Capital Markets | Buy |
View All
Orchestra Biomed Holdings Inc Stock (OBIO) Latest News
Haemonetics (HAE) Acquisition of Vivasure Boosts Orchestra BioMed's Finances - GuruFocus
Orchestra BioMed Holdings, Inc. to Receive Proceeds from Vivasure Acquisition - TradingView — Track All Markets
Early bet on vessel-closure patch could bring this firm $21M windfall - Stock Titan
Assessing Orchestra BioMed Hldgs: Insights From 4 Financial Analysts - Benzinga
Orchestra BioMed Holdings, Inc.'s (NASDAQ:OBIO) market cap touched US$251m last week, benefiting both retail investors who own 41% as well as institutions - Sahm
Can Orchestra BioMed Holdings Inc. stock continue upward trendForecast Cut & Long-Term Growth Portfolio Plans - ulpravda.ru
Can Orchestra BioMed Holdings Inc. stock rebound after recent weakness2025 Historical Comparison & Weekly Watchlist of Top Performers - ulpravda.ru
Published on: 2026-01-09 01:26:31 - ulpravda.ru
Is Orchestra BioMed Holdings Inc. stock a dividend growth opportunityJuly 2025 Update & Daily Chart Pattern Signal Reports - ulpravda.ru
Is Orchestra BioMed Holdings Inc. stock a safe buy before earningsBreakout Watch & Daily Profit Focused Stock Screening - ulpravda.ru
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Receives Consensus Recommendation of “Moderate Buy” from Analysts - Defense World
Orchestra BioMed (NASDAQ:OBIO) Shares Up 0.2% – Here’s Why - Defense World
TD Cowen Initiates Orchestra BioMed (OBIO), Cites High-Margin Potential in Lead Cardiovascular Programs - Insider Monkey
Orchestra BioMed to Highlight Advancements in Cardiac Therapy at HRS 2025 - MSN
Orchestra BioMed Grants New Hire Stock Options as Clinical Programs Advance - MSN
What drives Orchestra BioMed Holdings Inc stock priceEarnings Beat Highlights & Receive Monthly Expert Trading Blueprints - earlytimes.in
Orchestra BioMed Holdings, Inc.(NasdaqGM: OBIO) added to NASDAQ Biotechnology Index - marketscreener.com
Why Orchestra BioMed Holdings Inc. stock is in analyst buy zone2025 Top Decliners & Low Risk High Win Rate Stock Picks - Улправда
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q4 Loss, Lags Revenue Estimates - MSN
Buyout Rumor: Can Orchestra BioMed Holdings Inc. stock rebound after recent weaknessPortfolio Gains Summary & Capital Protection Trade Alerts - Улправда
What dividend safety score for Orchestra BioMed Holdings Inc. stockWeekly Stock Recap & AI Based Buy/Sell Signal Reports - DonanımHaber
S P Trends: Is Orchestra BioMed Holdings Inc stock a safe buy before earningsQuarterly Portfolio Summary & Reliable Breakout Stock Forecasts - moha.gov.vn
Why Orchestra BioMed Holdings Inc. stock is favored by top institutionsRisk Management & Growth Focused Investment Plans - Улправда
Will Orchestra BioMed Holdings Inc. stock maintain growth storyDollar Strength & Verified High Yield Trade Plans - Улправда
Can Orchestra BioMed Holdings Inc. stock deliver consistent earnings growthMarket Sentiment Summary & Fast Entry Momentum Trade Alerts - Улправда
How Orchestra BioMed Holdings Inc. stock performs in high volatility marketsJuly 2025 Chart Watch & Growth Focused Stock Pick Reports - bollywoodhelpline.com
Weekly Trades: What dividend safety score for Orchestra BioMed Holdings Inc stockPortfolio Risk Report & Long Hold Capital Preservation Tips - moha.gov.vn
Chmn Hochman Surrenders 43,638 Of Orchestra BioMed Holdings Inc [OBIO] - TradingView — Track All Markets
Orchestra BioMed Holdings, Inc. (OBIO) CFO has 8,670 shares withheld for taxes - Stock Titan
Orchestra BioMed (OBIO) CEO details RSU-related tax share withholding by insider - Stock Titan
Orchestra BioMed (NASDAQ:OBIO) Now Covered by Analysts at TD Cowen - Defense World
TD Cowen Initiates Coverage of Orchestra BioMed Holdings (OBIO) with Buy Recommendation - Nasdaq
TD Cowen initiates Orchestra BioMed stock with Buy rating on novel medical device portfolio - Investing.com Nigeria
TD Cowen Initiates Orchestra BioMed Holdings at Buy With $15 Price Target - marketscreener.com
Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Orchestra BioMed and Medtronic Unveil Promising Hypertension Therapy Advances - Zenopa
Orchestra BioMed Announces AVIM Therapy and Virtue SAB Program Presentations at ICI Meeting - Investing News Network
Orchestra BioMed announces AVIM Therapy and Virtue SAB Program presentations at ICI Meeting - marketscreener.com
Orchestra BioMed and Medtronic Leadership to Present on Strategic Collaboration for AVIM Therapy at 2025 Innovation in Cardiology Intervention Meeting - Quiver Quantitative
Analyst Confidence in Orchestra BioMed Holdings (OBIO) High Amid Key Clinical and Strategic Advancements - MSN
What insider trading reveals about Orchestra BioMed Holdings Inc. stockShort Setup & AI Powered Market Trend Analysis - Newser
Orchestra BioMed Enters New Agreement with Terumo for Virtue SAB Device - globallegalchronicle.com
Wall Street Recap: Can Orchestra BioMed Holdings Inc. stock deliver consistent earnings growth2025 Macro Impact & Weekly High Return Stock Forecasts - moha.gov.vn
Orchestra BioMed Reports 2024 Financial Results and Advances Cardiovascular Therapy - MSN
12 Hot Penny Stocks to Invest in Right Now - Insider Monkey
A better buy-in window may exist right now for Orchestra BioMed Holdings Inc (OBIO) - Setenews
Orchestra BioMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Orchestra Biomed Holdings Inc Stock (OBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.51%
2.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):